BiotechTube
Recognify Life Sciences

Recognify Life Sciences

San Diego, United States· Est.
recognify.life
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

Recognify Life Sciences is a San Diego-based biotech, founded in 2020, developing RL-007, a novel GABAB/cholinergic modulator for cognitive impairment. The company is a subsidiary of atai Life Sciences and is led by a team with deep CNS and pharmaceutical development expertise. Its primary focus is advancing RL-007 into Phase 2 trials for CIAS, addressing a significant unmet need with no currently approved therapies.

NeurosciencePsychiatry

Technology Platform

Focused on a novel GABAB/cholinergic modulator (RL-007) designed to enhance hippocampal plasticity and pro-cognitive activity, rather than a broad, multi-asset platform.

Funding History

1
Total raised:$15M
Series A$15M

Opportunities

The primary opportunity is addressing the large, untreated market of Cognitive Impairment Associated with Schizophrenia (CIAS), which has no approved therapies and affects millions globally.
Success in CIAS could enable expansion into even larger cognitive impairment markets, such as Alzheimer's disease.
Being a subsidiary of atai provides strategic support and potential operational synergies within a network of mental health-focused companies.

Risk Factors

The company faces high binary risk as its value is tied to a single, unproven clinical asset (RL-007).
There is significant risk of clinical failure in upcoming Phase 2 trials for CIAS.
The regulatory pathway for a cognitive endpoint, while established, requires complex and costly trials to demonstrate clear efficacy.

Competitive Landscape

The competitive landscape for CIAS is characterized by high unmet need and active research, but no currently approved pharmacological treatments. Recognify competes with other biotech and large pharma companies developing pro-cognitive agents for schizophrenia, but its specific GABAB/cholinergic mechanism is novel. Its most significant competition may come from cognitive remediation therapies and other neuromodulatory approaches in development.

More companies in Neuroscience & CNS →More companies in United States →